To validate PDGFRA gene gain/amplification performed by our NGS panel, we conducted MLPA on 15 selective GBM cases, comprising 3 defined by NGS as showing PDGFRA gain (copy number range: 3-5), 5 defined by NGS as showing PDGFRA amplification (copy number range >5), and 7 defined by NGS as lacking PDGFRA gain/amplification (copy number range: 1-3). The gene discussed is PDGFRA; the disease is glioblastoma.